Skip to main content

Advertisement

SpringerLink
Log in

Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma

  • Short Communication
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

The chemotherapeutic regimen melphalan, prednisolone, and thalidomide (MPT) is the standard of care for symptomatic multiple myeloma patients who are not eligible for high dose chemotherapy followed by autologous stem cell therapy. Lenalidomide, a newer thalidomide derivative, is 300 times more potent than thalidomide. Combined therapy using melphalan, prednisolone, and lenalidomide (MPL) is very effective with many advantages. We report here one rare adverse effect, i.e., intrahepatic cholestasis related to lenalidomide, in two patients out of a total of 65 newly diagnosed cases of multiple myeloma receiving MPL regimen in our series. As the use of lenalidomide will increase in the future for multiple myeloma and other diseases, clinicians should be aware of this entity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487–2498

    Article  PubMed  CAS  Google Scholar 

  2. Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 367:825–831

    Article  PubMed  CAS  Google Scholar 

  3. Rajkumar SV, Hayman SR, Lacy MQ et al (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:4050–4053

    Article  PubMed  CAS  Google Scholar 

  4. Gupta D, Treon SP, Shiimay et al (2011) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15:1950–1961

    Article  Google Scholar 

  5. Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its IMID derivative as anticancer agents. Nat Rev Cancer 4:314–322

    Article  PubMed  CAS  Google Scholar 

  6. Rajkumar SV, Harousseau JL, Durie B, J Richardson P et al (2011) Guidelines for the uniform reporting of clinical trials: report of the 2009 International Myeloma Workshop Consensus Panel I. Blood (in print)

  7. Gay F, Hayman SR, Lacy M et al (2010) Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 115:1343–50

    Article  PubMed  CAS  Google Scholar 

  8. Palumbo A, Falco P, Corradini P, Falcone A et al (2007) Melphalan, prednisolone and linalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian Multiple Myeloma Network. J Clin Oncol 25:4459–65

    Article  PubMed  CAS  Google Scholar 

  9. Weber DM, Chen C, Niezvizky R, Wang M et al (2007) Linalidomide plus dexamethasone for relapse multiple myeloma in North America. N Engl J Med 357:2133–42

    Article  CAS  Google Scholar 

  10. Rao KV (2007) Lenalidomide in the treatment of multiple myeloma. Am J Health Syst Pharm 64(17):1799–1807

    Article  PubMed  CAS  Google Scholar 

  11. Hussain S, Browne R, Chen J, Parekh S (2007) Lenalidomide-induced severe hepatotoxicity. Blood 110(10):3814

    Article  PubMed  CAS  Google Scholar 

  12. Hussain MA (2005) Lenalidomide: patient management strategies. Semin Hematol 42:522–525

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Hematology, S.C.B. Medical College and Hospital, Cuttack, 753007, Odisha, India

    Rabindra Kumar Jena

  2. Pharmacology Department, Clinical Pharmacology Unit, S.C.B. Medical College and Hospital, Cuttack, 753007, Odisha, India

    Trupti Rekha Swain

  3. Medicine Department, S.C.B. Medical College and Hospital, Cuttack, 753007, Odisha, India

    Sandeep Sadashivrao Kansurkar

  4. Department of Biochemistry, S.C.B. Medical College and Hospital, Cuttack, 753007, Odisha, India

    Manorama Swain

Authors
  1. Rabindra Kumar Jena
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Trupti Rekha Swain
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sandeep Sadashivrao Kansurkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Manorama Swain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rabindra Kumar Jena.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jena, R.K., Swain, T.R., Kansurkar, S.S. et al. Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma. Eur J Clin Pharmacol 68, 881–884 (2012). https://doi.org/10.1007/s00228-011-1152-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-011-1152-y

Keywords

Search

Navigation